Table 2.
First-line treatment options and outcome expressed in months for the 834 patients
| Treatment | N | PFSa | Median OSa | % 2y survival |
|---|---|---|---|---|
| RT + TMZ regimens | 509 | 8.8 (8.1–9.5) | 16.1 (14.9–17.4) | 25.30% |
| Concomitant/adjuvant TMZ | 435 | 8.9 (8.0–9.7) | 16.4 (15.0–17.8) | 25.50% |
| BCNU wafers plus TMZb | 53 | 8.7 (7.1–10.4) | 18.8 (13.5–24.1) | 30.10% |
| Adjuvant TMZ alone | 21 | 6.6 (4.4–8.9) | 10.7 (5.7–15.7) | 8.00% |
| RT alonec | 70 | 3.4 (2.6–4.3) | 7.2 (5.6–8.9) | 2.30% |
| RT plus BCNU wafers | 23 | 6.0 (4.0–8.1) | 8.7 (4.7–12.8) | 12.90% |
| Clinical Trials | 46 | 6.5 (5.2–7.7) | 16.1 (9.6–22.6) | 26.00% |
| No treatment | 186 | – | 2.0 (1.7–2.4) | 0.00% |
aExpressed as median, in months, (95% C.I.).
b43 patients received concomitant/adjuvant TMZ and 10 only adjuvant TMZ.
c47.1% of patients received hypofractioned schedules or did not complete the total 60 Gy standard dose.